Sveriges Riksbank
RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
| Auction date | 2025-05-30 |
| Loan | 1061 |
| Coupon | 0.75 % |
| ISIN-code | SE0011281922 |
| Maturity | 2029-11-12 |
| Tendered volume, SEK mln | 1500 +/- 1500 |
| Total bid volume, SEK mln | 6,225 |
| Volume sold, SEK mln | 1,500 |
| Number of bids | 15 |
| Number of accepted bids | 1 |
| Average yield | 1.977 % |
| Lowest yield | 1.977 % |
| Highest accepted yield | 1.977 % |
| % accepted at highest yield | 100.00 |
| Auction date | 2025-05-30 |
| Loan | 1056 |
| Coupon | 2.25 % |
| ISIN-code | SE0004517290 |
| Maturity | 2032-06-01 |
| Tendered volume, SEK mln | 1200 +/- 1200 |
| Total bid volume, SEK mln | 4,325 |
| Volume sold, SEK mln | 1,200 |
| Number of bids | 15 |
| Number of accepted bids | 3 |
| Average yield | 2.143 % |
| Lowest yield | 2.140 % |
| Highest accepted yield | 2.145 % |
| % accepted at highest yield | 100.00 |
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
F. Hoffmann-La Roche Ltd31.5.2025 14:05:00 CEST | Press release
New data show Roche’s Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
Ipsen Pharma31.5.2025 14:00:00 CEST | Press release
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
WithSecure Oyj31.5.2025 08:45:00 CEST | Press release
WithSecure has completed the transaction of Cyber security consulting divestment to Neqst
Teva Pharmaceutical Industries Ltd31.5.2025 03:05:00 CEST | Press release
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
Teva Pharmaceutical Industries Ltd31.5.2025 03:00:00 CEST | Press release
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom